07:24 AM EDT, 09/12/2024 (MT Newswires) -- Aura Biosciences ( AURA ) said Thursday that a mid-stage study of its experimental therapy, bel-sar, to treat early-stage choroidal melanoma showed positive results.

The study of bel-sar demonstrated an 80% tumor control rate among late-stage-eligible patients, with tumor growth stopping completely in responders.

The company said 90% of patients in therapy showed their ability to distinguish shapes and the details at a given distance preserved.

Bel-sar also showed a favorable safety profile with no serious adverse events.

The company said it would continue its enrolment of patients in the ongoing global late-stage trial.

Shares of the drug developer were up more than 6% in recent Thursday premarket activity.

Price: 9.66, Change: +0.59, Percent Change: +6.50